Rudolph M. Navari, MD, PhD, FACP

Assistant Dean & Professor of Medicine

Indiana University School of Medicine South Bend

Clinical Director, Harper Cancer Research Institute

Education
BS, University of Notre Dame, 1966
MS, University of Virginia, 1968
PhD, University of Virginia, 1970
MD, Medical College of Virginia, 1977                                     

Contact
Phone: (574) 631-3793
Fax: (574) 631- 4939
E-mail: rnavari@nd.edu

Research Focus
Dr. Navari’s research interests include supportive care in clinical oncology, development of antiemetics, palliative care, and the doctor-patient relationship in clinical oncology.

Selected Recent Publications
Navari RM. (2006).  Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomiting. Cancer Treat Rev. 32:50-54.

Busquets L, Guillen H, DeFord ME, Suckow MA, Navari RM, Castellino FJ, Prorok M. (2006).  Cathepsin E is a specific marker of dysplasia in APC mouse intestine. Tumour Biol. 27:36-42.

Navari RM, Einhorn LH, Passik SD et al. (2005).  A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting. Support Care Cancer. 13: 529 - 534.

Navari RM. (2005).  Advances in the treatment of chemotherapy-induced nausea and vomiting. Hospital Pharmacy Europe. 20: 37-40.

Reinbolt RE, Shenk AM, White PH, Navari RM. (2005). Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Pain Symptom Manage. 30:175-182.